0.5499
22-November-24 16:00:02
15 minutes delayed
Stocks
-0.0201
-3.53%
Today's range
0.5331 - 0.5996
ISIN
N/A
Source
NASDAQ
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina
08 Nov 2024 06:00:00 By Nasdaq GlobeNewswire
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
22 Dec 2023 07:00:00 By Nasdaq GlobeNewswire